From discovery to human-relevant evidence: the next phase of biotech R&D

Biotech research and development is starting to combine artificial intelligence with methods designed to reflect human biology. These approaches may help teams identify promising candidates earlier and generate more relevant evidence before clinical development. Turning that potential into routine practice will require scientific rigour, regulatory alignment and a credible path to adoption.
Bringing human biology closer to early development
Animal models have played a central role in preclinical research, but they do not always predict human outcomes. New Approach Methodologies (NAMs), including organ-on-chip and other human-relevant models, offer additional ways to investigate how a potential therapy may behave. AI-enabled discovery can accelerate parts of candidate identification. Used appropriately, these tools can support better-informed decisions about which programmes to advance.
Regulatory pathways are evolving
Regulatory frameworks are beginning to accommodate non-animal methods and AI-supported evidence, but acceptance remains specific to the method, application and market. Biotech companies need to understand what evidence is required and how each approach can be integrated into a development programme.
Consolidation, succession and the search for scale
Succession, rising operational demands and the need for scale are reshaping ownership across the sector. Consolidation can help businesses professionalise, fund investment and build broader platforms. But acquisition activity alone does not create value. With consolidation expected to continue in the coming years, investors need to identify businesses with the foundations to grow and understand how each could contribute to a stronger platform.
From a promising result to repeatable use
Strong results alone do not guarantee adoption. Reproducibility, standardisation, validation and clear regulatory pathways influence whether a method can be applied beyond a pilot. For technology providers, repeat programmes and broader deployment are also important tests of commercial traction.
The investment case depends on value capture
More predictive testing and AI-enabled workflows may affect the timing and economics of research and development. The impact will vary by technology and business model, and will depend on whether better evidence translates into improved decisions, repeat use and sustainable value creation.
How Eight International can support you
We support biotech companies and investors in assessing the strategic and financial potential of NAMs and AI-enabled approaches, including their implications for value creation.
Download the full report for the analysis and recommendations.
